Table 3 Characteristics of the patients with LDL cholesterol <2.6 mmol/L according to the presence of atherogenic dyslipidemia
|  | No atherogenic dysplipidemia n = 549 | Atherogenic dysplipidemia n = 35 | p |
|---|---|---|---|
Clinical characteristics | |||
 Age, years | 61.6 ± 9.0 | 60.6 ± 7.4 | 0.001 |
 Gender, male/female | 334/215 | 24/11 | 0.36 |
 Body mass index, kg/m2 | 30.1 ± 6.0 | 31.0 ± 5.0 | 0.001 |
Diabetes | |||
 Diabetes duration, years | 14.0 ± 8.4 | 12.0 ± 7.3 | 0.003 |
 HbA1c, % | 8.4 ± 1.9 | 9.0 ± 2.0 | 0.006 |
 Retinopathy, % | 180 (34.0) | 10 (26.8) | 0.51 |
 Nephropathy, % | 212 (60.1) | 16 (69.6) | 0.37 |
 Peripheral neuropathy, % | 111 (45.9) | 10 (58.8) | 0.30 |
 Peripheral arterial occlusive disease, % | 59 (11.2) | 6 (18.2) | 0.22 |
 Family history of premature CAD, % | 67 (12.5) | 8 (23.5) | 0.07 |
Additional cardiovascular risk factors | |||
 Hypertension, % | 207 (80.5) | 13 (72.2) | 0.39 |
 Lipid parameters | |||
  Total cholesterol, mmol/L | 4.1 ± 0.6 | 4.4 ± 0.7 | 0.013 |
  HDL cholesterol, mmol/L | 1.4 ± 0.5 | 0.8 ± 0.1 | 0.073 |
  Triglycerides, mmol/L | 1.5 ± 0.9 | 3.7 ± 1.3 | 0.24 |
  LDL cholesterol, mmol/L | 2.0 ± 0.4 | 1.9 ± 0.4 | 0.003 |
  Non-HDL cholesterol, mmol/L | 2.7 ± 0.6 | 3.6 ± 0.7 | <0.0001 |
  Apoprotein A1, g/L | 1.47 ± 0.29 | 1.13 ± 0.13 | 0.001 |
  Apoprotein B, g/L | 0.79 ± 0.16 | 0.91 ± 0.14 | 0.045 |
Fibrate treatment, % | 41 (7.6) | 6 (17.6) | <0.05 |
Statin treatment, % | 279 (52.1) | 15 (44.1) | 0.37 |
Smoking, % | 126 (23.1) | 12 (34.2) | 0.13 |